PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature

Research output: Contribution to journalReviewResearchpeer-review

Documents

  • fon.14.139

    Final published version, 2 MB, PDF document

Camilla Bardram Johnbeck, Ulrich Knigge, Andreas Kjær

Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. (68)Ga-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison of sensitivity between the most used tracers - (68)Ga-DOTA-Tyr3-octreotide, (68)Ga-DOTA-Tyr3-octreotate and (68)Ga-DOTA-l-Nal3-octreotide - shows little difference and expertise on the specific tracer used, and knowledge regarding physiological uptake might be more important than in vitro-proven differences in affinity. Using isotopes such as (18)F or (64)Cu might improve these PET tracers further.

Original languageEnglish
JournalFuture Oncology
Volume10
Issue number14
Pages (from-to)2259-2277
Number of pages19
ISSN1479-6694
DOIs
Publication statusPublished - Nov 2014

Number of downloads are based on statistics from Google Scholar and www.ku.dk


No data available

ID: 137324436